CA2222318A1 - Utilisation d'alendronate pour prevenir l'osteoporose - Google Patents

Utilisation d'alendronate pour prevenir l'osteoporose Download PDF

Info

Publication number
CA2222318A1
CA2222318A1 CA002222318A CA2222318A CA2222318A1 CA 2222318 A1 CA2222318 A1 CA 2222318A1 CA 002222318 A CA002222318 A CA 002222318A CA 2222318 A CA2222318 A CA 2222318A CA 2222318 A1 CA2222318 A1 CA 2222318A1
Authority
CA
Canada
Prior art keywords
alendronate
osteoporosis
bone
years
aln
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002222318A
Other languages
English (en)
Inventor
J. Yates Ashley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2222318A1 publication Critical patent/CA2222318A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'alendronate qui est un aminobisphosphate peut s'utiliser pour prévenir l'ostéoporose postménopausique précoce.
CA002222318A 1995-06-02 1996-05-29 Utilisation d'alendronate pour prevenir l'osteoporose Abandoned CA2222318A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45819595A 1995-06-02 1995-06-02
US08/458,195 1995-06-02

Publications (1)

Publication Number Publication Date
CA2222318A1 true CA2222318A1 (fr) 1996-12-05

Family

ID=23819759

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002222318A Abandoned CA2222318A1 (fr) 1995-06-02 1996-05-29 Utilisation d'alendronate pour prevenir l'osteoporose

Country Status (21)

Country Link
EP (1) EP0828496A1 (fr)
JP (1) JPH10506648A (fr)
KR (1) KR19990022436A (fr)
CN (1) CN1192685A (fr)
AU (1) AU709196B2 (fr)
BG (1) BG63103B1 (fr)
BR (1) BR9609020A (fr)
CA (1) CA2222318A1 (fr)
CZ (1) CZ381197A3 (fr)
EA (1) EA000677B1 (fr)
EE (1) EE03306B1 (fr)
HU (1) HUP9900659A3 (fr)
IL (1) IL118422A0 (fr)
IS (1) IS4617A (fr)
NO (1) NO975527D0 (fr)
NZ (1) NZ308935A (fr)
PL (1) PL323669A1 (fr)
SK (1) SK159597A3 (fr)
TR (1) TR199701482T1 (fr)
WO (1) WO1996038156A1 (fr)
ZA (1) ZA964465B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010031244A1 (en) 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
SE9901272D0 (sv) * 1999-04-09 1999-04-09 Astra Ab New improved formulation
KR100317935B1 (ko) * 1999-10-20 2001-12-22 유승필 대사성 골질환 치료용 약제조성물 및 이의 제조방법
JP2004528365A (ja) * 2001-05-02 2004-09-16 ノバルティス アクチエンゲゼルシャフト 骨再吸収症および骨粗しょう症の処置または予防におけるビスホスホネートの吸入投与方法
JP2010043119A (ja) * 2009-10-16 2010-02-25 Gador Sa 骨の代謝病の予防および／または治療のための組成物、その組成物の調製方法およびその使用
KR102472749B1 (ko) * 2022-01-18 2022-12-02 주식회사 위엔씨 유해가스제거 및 항균탈취기능을 함유한 흡착소재 제조방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366965A (en) * 1993-01-29 1994-11-22 Boehringer Mannheim Gmbh Regimen for treatment or prophylaxis of osteoporosis
US5462932A (en) * 1994-05-17 1995-10-31 Merck & Co., Inc. Oral liquid alendronate formulations

Also Published As

Publication number Publication date
NO975527L (no) 1997-12-01
EP0828496A1 (fr) 1998-03-18
EE03306B1 (et) 2000-12-15
EA000677B1 (ru) 2000-02-28
HUP9900659A3 (en) 2002-12-28
IL118422A0 (en) 1996-09-12
BR9609020A (pt) 1999-07-06
HUP9900659A2 (hu) 2001-04-28
CN1192685A (zh) 1998-09-09
ZA964465B (en) 1996-12-11
AU709196B2 (en) 1999-08-26
WO1996038156A1 (fr) 1996-12-05
KR19990022436A (ko) 1999-03-25
SK159597A3 (en) 1998-06-03
NO975527D0 (no) 1997-12-01
CZ381197A3 (cs) 1998-06-17
IS4617A (is) 1997-11-19
JPH10506648A (ja) 1998-06-30
NZ308935A (en) 2000-07-28
AU5882496A (en) 1996-12-18
TR199701482T1 (xx) 1998-03-21
EA199700449A1 (ru) 1998-06-25
BG63103B1 (bg) 2001-04-30
PL323669A1 (en) 1998-04-14
BG102060A (en) 1998-07-31

Similar Documents

Publication Publication Date Title
AU2009238379B2 (en) Folic acid-containing pharmaceutical compositions, and related methods and delivery systems
Seeman et al. Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older
CA2258525A1 (fr) Contraceptif oral a combinaison pharmaceutique oestrogenes-androgenes-progestine
EA000964B1 (ru) Способ лечения или предупреждения остеопороза
AU690431B2 (en) Method of lessening the risk of non-vertebral bone fractures
KR20010015918A (ko) 안면홍조를 감소시키기 위한 플루옥세틴 히드로클로라이드
Goa et al. Risedronate.
US20010046977A1 (en) Use of alendronate for the prevention of osteoporosis
AU709196B2 (en) Use of alendronate for the prevention of osteoporosis
US5914099A (en) Prevention of tooth loss by the administration of alendronate or its salts
KR19980702209A (ko) 척추 골절의 위험을 경감시키는 방법
AU692155B2 (en) Method and composition for treatment of osteoporosis
Standard Pr TEVA-RISEDRONATE
AU719771B2 (en) Intravenous alendronate formulations
MXPA97009426A (en) Use of alendronate to prepare compositions for the prevention of osteoporo
MXPA97009906A (en) Use of bisphosphonates to prepare compositions to prevent loss of associated bone conterapia immunosupres
MXPA97006277A (en) The use of alendronate to prepare compositions to reduce the risk of non-vertebrate bit fractures

Legal Events

Date Code Title Description
FZDE Discontinued